SCHEMBL16610837

SCHEMBL16610837

COc1nccc2c1c(-c1ccc(N3CCOCC3)cc1)nn2C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.44
GSK3B P49841 1/20 0.41
FYN P06241 1/20 0.39
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37
CCNB1 P14635 1/20 0.37
CCNA2 P20248 1/20 0.37
CCND1 P24385 1/20 0.37
CDK2 P24941 1/20 0.37
CDK7 P50613 1/20 0.37
CCNH P51946 1/20 0.37
PRKDC P78527 2/20 0.37
KCNH2 Q12809 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
HPGD P15428 3/20 0.37
MAPT P10636 2/20 0.37
HSD17B10 Q99714 2/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610876 0.80 SLC18A3 (0.41) LRRK2GSK3BFYNPRKDCKCNH2
SCHEMBL16610911 0.79 TSHR (0.41) LRRK2GSK3BFYNCDK1CDK4
SCHEMBL16610962 0.79 MAP4K1 (0.41) LRRK2GSK3BFYNCDK1CDK4
SCHEMBL16611339 0.78 LRRK2 (0.39) LRRK2GSK3BFYNPRKDCKCNH2
SCHEMBL16611010 0.77 LRRK2 (0.38) LRRK2GSK3BFYNCDK1CDK4
SCHEMBL16610846 0.76 LRRK2 (0.43) LRRK2PRKDCPIK3CAMTORPIK3CD
SCHEMBL16611792 0.75 ZAP70 (0.42) PRKDCPIK3CAPIK3CDSYK
SCHEMBL16611322 0.74 TBK1 (0.43) LRRK2GSK3BCDK1CDK4CCNB1
SCHEMBL16610949 0.74 LRRK2 (0.74) LRRK2
SCHEMBL16611763 0.73 CCNA2 (0.43) LRRK2GSK3BCDK1CDK4CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LRRK2 1393/4885GSK3B 3280/4885FYN 712/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 LRRK2 1393/4885GSK3B 3280/4885FYN 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.